Subscribe

Femasys Inc. (FEMY)

USD3.57 -0.03 (-0.83%)
US NASDAQ Healthcare Medical - Instruments & Supplies
Address 3950 Johns Creek Court 30024
Suwanee, GA, US
CEO Kathy Lee-Sepsick
Website femasys.com
IPO 2021-06-18
CIK 1339005 ISIN US31447E2046

Explore sections of this company profile

Description

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD3.57 -0.03 (-0.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
60.6K
Beta
-2.22
Float Shares
22.86M
Free Float %
77.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-6.70% -18.13% -5.01% -23.04% -60.81% -34.55% -65.08% -49.38% -96.86% -96.86% -96.86%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (5 ratings, all time) Buy
Price Targets & DCF
Current price
3.57
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 2 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-13.87
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Instruments & Supplies: +7.9%
    +40.8% ★ Q1'26: +24.5% (vs Q1'25)
  • ✗
    EPS growth Medical - Instruments & Supplies: +16.3%
    +44.1% ★ Q1'26: +101.8% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    -887.8% Q1'26: -993.8% (vs Q1'25)
  • ✗
    EBIT margin Medical - Instruments & Supplies: +13.5%
    -729.8% Q1'26: -994.0% (vs Q1'25)
  • ✗
    ROIC Medical - Instruments & Supplies: +6.0%
    -1,287.4% Q1'26: -152.8% (vs Q1'25)
  • ✗
    Share dilution Medical - Instruments & Supplies: +0.1%
    +77.6% Q1'26: +210.5% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    -0.30× Q1'26: -0.29× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-2.26) × ERP
WACC = 79% × Ke + 21% × Kd (40.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 3.57
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
2 EPS Ana. 		Dec 2027
3 Rev. Ana.
2 EPS Ana. 		Dec 2028
3 Rev. Ana.
3 EPS Ana. 		Dec 2029
2 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
1.18M
est: 1.20M (-1.7%)
1.21M
est: 1.32M (-8.9%)
1.07M
est: 950.1K (+12.8%)
1.63M
est: 2.71M (-39.9%)
2.29M
est: 2.55M (-9.9%)
5.41M
5.20M – 5.74M
+112.4% YoY
13.85M
13.75M – 14.00M
+156.1% YoY
32.65M
32.65M – 32.65M
+135.8% YoY
66.43M
63.90M – 70.50M
+103.5% YoY
126.35M
121.53M – 134.09M
+90.2% YoY
EBITDA
-6.55M
est: -1.20M (-445.9%)
-10.49M
est: -1.32M (-692.2%)
-13.17M
est: -950.1K (-1,286.1%)
-16.33M
est: -2.71M (-502.2%)
-15.89M
est: -2.55M (-523.8%)
-5.41M
-5.74M – -5.20M
-112.4% YoY
-13.85M
-14.00M – -13.75M
-156.1% YoY
-32.65M
-32.65M – -32.65M
-135.8% YoY
-66.43M
-70.50M – -63.90M
-103.5% YoY
-126.35M
-134.09M – -121.53M
-90.2% YoY
EBIT
-7.51M
est: -1.20M (-526.2%)
-11.37M
est: -1.32M (-759.4%)
-14.08M
est: -950.1K (-1,381.7%)
-17.20M
est: -2.71M (-534.3%)
-16.74M
est: -2.55M (-557.2%)
-5.41M
-5.74M – -5.20M
-112.4% YoY
-13.85M
-14.00M – -13.75M
-156.1% YoY
-32.65M
-32.65M – -32.65M
-135.8% YoY
-66.43M
-70.50M – -63.90M
-103.5% YoY
-126.35M
-134.09M – -121.53M
-90.2% YoY
Net Income
-7.54M
est: -20.49M (+63.2%)
-11.39M
est: -22.14M (+48.5%)
-14.25M
est: -33.28M (+57.2%)
-18.82M
est: -32.21M (+41.6%)
-18.63M
est: -21.01M (+11.3%)
-12.58M
-13.38M – -11.78M
+40.1% YoY
-11.60M
-12.42M – -10.78M
+7.8% YoY
-11.05M
-13.84M – 3.56M
+4.8% YoY
4.88M
4.64M – 5.27M
+144.1% YoY
29.86M
28.38M – 32.24M
+512.2% YoY
SGA
4.47M
est: 5.97M (-25.1%)
5.99M
est: 6.58M (-9.0%)
7.51M
est: 5.12M (+46.6%)
10.36M
est: 14.62M (-29.2%)
11.09M
est: 13.73M (-19.2%)
29.15M
28.04M – 30.94M
+112.4% YoY
74.65M
74.10M – 75.47M
+156.1% YoY
176.00M
176.00M – 176.00M
+135.8% YoY
358.09M
344.43M – 380.03M
+103.5% YoY
681.07M
655.08M – 722.78M
+90.2% YoY
EPS
-0.64
est: -0.92 (+30.4%)
-0.97
est: -0.98 (+1.0%)
-0.93
est: -0.83 (-12.2%)
-0.84
est: -0.80 (-4.7%)
-0.47
est: -0.52 (+10.2%)
-0.31
-0.34 – -0.30
+40.1% YoY
-0.29
-0.31 – -0.27
+6.4% YoY
-0.16
-0.35 – 0.09
+45.5% YoY
0.12
0.12 – 0.13
+177.1% YoY
0.76
0.72 – 0.82
+512.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-05-01 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-17.73M
OE per share TTM
-0.60
Owner's Yield
-98.95%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
224.0%

Ownership Overview

Ownership breakdown
At a glance
Institutional holders
13
Total invested
109.7K
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 PharmaCyte Biotech, Inc. 12.71M 37.00% 12.71M — 12.71M 10.00 CO Nevada 2023-11-22 ↗

Institutional Activity (13F)

Institutional ownership trend From To
13F snapshot — 2026 Q1
Investors holding
13
-25 vs prev Q
New positions
3
Closed positions
28
Increased
4
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
# Investor ⇅ Shares / Δ ⇅ Mkt value / Δ ⇅ Own% / Δ ⇅ Weight% / Δ ⇅ Avg px / Perf. ⇅ Hold / Status ⇅
1 DAUNTLESS INVESTMENT GROUP, LLC 5.93M +4.2M (+242.4%) 849.5K +239.0K (+39.1%) 20.54% +14.540 pp 0.67% +0.293 pp USD0.75 -22.7% 4 qtrs —
2 VANGUARD GROUP INC 1.42M +463.7K (+48.7%) 815.4K +480.3K (+143.3%) 4.90% +1.606 pp 0.00% +0.000 pp USD0.99 -41.4% 16 qtrs —
3 GEODE CAPITAL MANAGEMENT, LLC 389.3K +131.1K (+50.8%) 224.3K +133.3K (+146.5%) 1.35% +0.454 pp 0.00% +0.000 pp USD1.34 -56.7% 10 qtrs —
4 CITADEL ADVISORS LLC 342.2K +342.2K (+100.0%) 197.2K +197.2K (+100.0%) 1.18% +1.185 pp 0.00% +0.000 pp USD0.58 +0.0% 5 qtrs —
5 BANCO BTG PACTUAL S.A. 152.2K +152.2K (+100.0%) 87.7K +87.7K (+100.0%) 0.53% +0.527 pp 0.02% +0.015 pp USD0.58 +0.0% 1 qtrs NEW
6 BLACKROCK, INC. 135.4K +36.6K (+37.1%) 78.0K +43.2K (+124.2%) 0.47% +0.127 pp 0.00% +0.000 pp USD0.89 -34.8% 6 qtrs —
7 CLEAR CREEK FINANCIAL MANAGEMENT, LLC 109.7K -29.2K (-21.1%) 63.2K +14.2K (+29.1%) 0.38% -0.101 pp 0.01% +0.001 pp USD2.30 -74.8% 18 qtrs —
8 JANE STREET GROUP, LLC 107.0K +107.0K (+100.0%) 61.7K +61.7K (+100.0%) 0.37% +0.371 pp 0.00% +0.000 pp USD0.58 +0.0% 5 qtrs —
9 UBS GROUP AG 90.9K +73.0K (+407.5%) 52.4K +46.1K (+730.5%) 0.31% +0.253 pp 0.00% +0.000 pp USD0.65 -10.8% 3 qtrs —
10 STATE STREET CORP 80.9K +24.5K (+43.5%) 46.6K +26.7K (+134.6%) 0.28% +0.085 pp 0.00% +0.000 pp USD0.89 -34.8% 9 qtrs —
11 NORTHERN TRUST CORP 75.4K +— (+0.0%) 43.4K +16.9K (+63.5%) 0.26% +0.000 pp 0.00% +0.000 pp USD0.87 -33.3% 9 qtrs —
12 CETERA INVESTMENT ADVISERS 62.0K +62.0K (+100.0%) 35.7K +35.7K (+100.0%) 0.21% +0.215 pp 0.00% +0.000 pp USD0.58 +0.0% 1 qtrs NEW
13 HRT FINANCIAL LP 52.8K +52.8K (+100.0%) 30.0K +30.0K (+100.0%) 0.18% +0.183 pp 0.00% +0.000 pp USD0.58 +0.0% 5 qtrs —
14 CITIGROUP INC 51.1K +51.1K (+100.0%) 29.4K +29.4K (+100.0%) 0.18% +0.177 pp 0.00% +0.000 pp USD0.58 +0.0% 1 qtrs NEW
15 ADVISOR GROUP HOLDINGS, INC. 47.1K +— (+0.0%) 27.3K +10.8K (+65.7%) 0.16% +0.000 pp 0.00% +0.000 pp USD0.97 -40.2% 3 qtrs —
16 NWF ADVISORY SERVICES INC. 47.1K +— (+0.0%) 27.1K +10.5K (+63.5%) 0.16% +0.000 pp 0.00% +0.001 pp USD1.08 -46.3% 12 qtrs —
17 KOVACK ADVISORS, INC. 46.8K +46.8K (+100.0%) 27.0K +27.0K (+100.0%) 0.16% +0.162 pp 0.00% +0.001 pp USD0.58 +0.0% 1 qtrs NEW
18 BAY RIVERS GROUP 33.3K +33.3K (+100.0%) 19.2K +19.2K (+100.0%) 0.12% +0.115 pp 0.01% +0.008 pp USD0.58 +0.0% 1 qtrs NEW
19 TWO SIGMA SECURITIES, LLC 31.2K +31.2K (+100.0%) 18.0K +18.0K (+100.0%) 0.11% +0.108 pp 0.00% +0.003 pp USD0.58 +0.0% 1 qtrs NEW
20 WEALTHSPIRE ADVISORS, LLC 28.1K +— (+0.0%) 16.2K +6.3K (+63.5%) 0.10% +0.000 pp 0.00% +0.000 pp USD2.98 -80.5% 10 qtrs —
21 TWO SIGMA INVESTMENTS, LP 26.1K +26.1K (+100.0%) 15.1K +15.1K (+100.0%) 0.09% +0.091 pp 0.00% +0.000 pp USD0.58 +0.0% 1 qtrs NEW
22 OCEAN CAPITAL MANAGEMENT, LLC 25.3K +— (+0.0%) 14.6K +5.7K (+63.5%) 0.09% +0.000 pp 0.00% +0.001 pp USD1.08 -46.3% 6 qtrs —
23 XTX TOPCO LTD 22.0K -22.1K (-50.0%) 12.7K -2.8K (-18.3%) 0.08% -0.076 pp 0.00% -0.001 pp USD0.66 -12.1% 10 qtrs —
24 VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC 21.1K +11.0K (+109.9%) 12.1K +8.6K (+243.3%) 0.07% +0.038 pp 0.00% +0.000 pp USD1.72 -66.3% 10 qtrs —
25 TRAYNOR CAPITAL MANAGEMENT, INC. 21.0K +21.0K (+100.0%) 12.1K +12.1K (+100.0%) 0.07% +0.073 pp 0.00% +0.001 pp USD0.58 +0.0% 1 qtrs NEW
26 NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 20.0K +— (+0.0%) 11.5K +4.5K (+63.5%) 0.07% +0.000 pp 0.00% +0.000 pp USD1.72 -66.3% 8 qtrs —
27 MARINER, LLC 18.7K +— (+0.0%) 10.8K +4.2K (+63.5%) 0.06% +0.000 pp 0.00% +0.000 pp USD1.14 -49.1% 14 qtrs —
28 WHITTIER TRUST CO OF NEVADA INC 15.9K +— (+0.0%) 9.4K -558.0 (-5.6%) 0.06% +0.000 pp 0.00% +0.000 pp USD1.13 -48.7% 14 qtrs —
29 CX INSTITUTIONAL 15.0K +— (+0.0%) 9.0K +4.0K (+80.0%) 0.05% +0.000 pp 0.00% +0.000 pp USD1.14 -49.1% 4 qtrs —
30 PANDORA WEALTH, INC. 15.0K +— (+0.0%) 8.6K +3.4K (+63.5%) 0.05% +0.000 pp 0.01% +0.002 pp USD1.25 -53.6% 4 qtrs —
31 HB WEALTH MANAGEMENT, LLC 11.1K -2.3K (-17.0%) 6.4K +1.7K (+35.7%) 0.04% -0.008 pp 0.00% +0.000 pp USD0.35 +65.7% 13 qtrs —
32 FMR LLC 7.5K +7.5K (+100.0%) 4.3K +4.3K (+100.0%) 0.03% +0.026 pp 0.00% +0.000 pp USD0.58 +0.0% 1 qtrs NEW
33 BANK OF AMERICA CORP /DE/ 3.1K +— (+0.0%) 1.8K +688.0 (+63.7%) 0.01% +0.000 pp 0.00% +0.000 pp USD2.57 -77.4% 15 qtrs —
34 FORTITUDE FAMILY OFFICE, LLC 2.9K +2.9K (+100.0%) 1.7K +1.7K (+100.0%) 0.01% +0.010 pp 0.00% +0.000 pp USD0.58 +0.0% 1 qtrs NEW
35 SOUTHSTATE CORP 2.2K +— (+0.0%) 1.3K +498.0 (+63.6%) 0.01% +0.000 pp 0.00% +0.000 pp USD0.35 +65.7% 2 qtrs —
36 TRUST CO OF TOLEDO NA /OH/ 1.8K +— (+0.0%) 1.0K +394.0 (+63.5%) 0.01% +0.000 pp 0.00% +0.000 pp USD0.97 -40.2% 3 qtrs —
37 IFP ADVISORS, INC 1.0K -1.0K (-50.0%) 576.00 -129.0 (-18.3%) 0.00% -0.004 pp 0.00% +0.000 pp USD0.35 +65.7% 2 qtrs —
38 SBI SECURITIES CO., LTD. 159.00 -1.0 (-0.6%) 92.00 +36.0 (+64.3%) 0.00% +0.000 pp 0.00% +0.000 pp USD1.08 -46.3% 5 qtrs —
39 ALLWORTH FINANCIAL LP — -2.6K (-100.0%) — -899.0 (-100.0%) 0.00% -0.009 pp 0.00% +0.000 pp USD— 7 qtrs SOLD
40 GLOBAL RETIREMENT PARTNERS, LLC — -33.0K (-100.0%) — -11.6K (-100.0%) 0.00% -0.114 pp 0.00% 0.000 pp USD— 3 qtrs SOLD
41 SUSQUEHANNA INTERNATIONAL GROUP, LLP — -31.6K (-100.0%) — -11.2K (-100.0%) 0.00% -0.110 pp 0.00% +0.000 pp USD— 2 qtrs SOLD
42 TOWER RESEARCH CAPITAL LLC (TRC) — -17.7K (-100.0%) — -6.2K (-100.0%) 0.00% -0.061 pp 0.00% 0.000 pp USD— 18 qtrs SOLD
43 CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. — -10.8K (-100.0%) — -4.0K (-100.0%) 0.00% -0.038 pp 0.00% +0.000 pp USD— 2 qtrs SOLD
44 VIRTU FINANCIAL LLC — -21.0K (-100.0%) — -7.0K (-100.0%) 0.00% -0.073 pp 0.00% 0.000 pp USD— 5 qtrs SOLD
45 MORGAN STANLEY — -275.0 (-100.0%) — -97.0 (-100.0%) 0.00% -0.001 pp 0.00% +0.000 pp USD— 18 qtrs SOLD
Ownership breakdown by holder

ETF Ownership

Top ETFs holding this stock Held by 11 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Vanguard Extended Market ETF VXF 0.00% 211.3K 0.05%
2 Vanguard U.S. Total Market Shares Index ETF VTS.AX 0.00% 508.10 0.03%
3 Vanguard U.S. Total Market Index ETF VUN.TO 0.00% 1.4K 0.17%
4 Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO 0.00% 103.05 0.17%
5 Vanguard Total Stock Market ETF VTI 0.00% 238.3K 0.03%
6 Vanguard All-Equity ETF Portfolio VEQT.TO 0.00% 522.11 0.22%
7 Vanguard Growth ETF Portfolio VGRO.TO 0.00% 284.19 0.22%
8 Vanguard Balanced ETF Portfolio VBAL.TO 0.00% 114.78 0.22%
9 Vanguard Conservative ETF Portfolio VCNS.TO 0.00% 12.63 0.22%
10 Vanguard Conservative Income ETF Portfolio VCIP.TO 0.00% 1.78 0.22%

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
11
Sells
0
Shares acquired
1.58M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,575,054
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2026-03-30 Canning John Charles Officer A-Award A Stock Option (Right to Buy) 150,000 0.38 57.0K 150,000 D ↗
2026-03-19 Lee-Sepsick Kathy Director / Officer A-Award A Series D-1 Warrants 68,244 0.58 39.6K 68,244 D ↗
2026-03-19 Larsen Charles Director A-Award A Series D-1 Warrants 34,122 0.58 19.8K 34,122 D ↗
2026-03-19 Elefant Dov Officer A-Award A Series D-1 Warrants 34,122 0.58 19.8K 34,122 D ↗
2026-03-19 Eichenbaum Kenneth D. Director A-Award A Series D-1 Warrants 102,366 0.58 59.4K 102,366 D ↗
2026-03-18 Eichenbaum Kenneth D. Director — — Common Stock 0 0.00 — 25,010 D ↗
2026-03-17 Silverman Joshua Director — — — 0 0.00 — 0 — ↗
2026-03-17 PharmaCyte Biotech, Inc. 10% Owner — — — 0 0.00 — 0 — ↗
2026-02-19 Lee-Sepsick Kathy Director / Officer A-Award A Restricted Stock Units 447,000 0.00 — 447,000 D ↗
2026-02-19 Elefant Dov Officer A-Award A Restricted Stock Units 169,000 0.00 — 169,000 D ↗
2026-02-02 Sipos Jeremy Alexander Officer A-Award A Restricted Stock Units 80,000 0.00 — 80,000 D ↗
2025-12-16 Sipos Jeremy Alexander Officer — — Employee Stock Option (Right to Buy) 34,700 1.05 36.4K 0 D ↗
2025-11-07 Lee-Sepsick Kathy Director / Officer I-Discretionary A Series A-1 Warrants 68,244 0.81 55.3K 68,244 D ↗
2025-11-07 Larsen Charles Director I-Discretionary A Series C-1 Warrants 34,122 1.10 37.5K 34,122 D ↗
2025-11-07 Elefant Dov Officer I-Discretionary A Senior Secured Convertible Notes 0 0.73 — 0 D ↗
2025-11-07 Eichenbaum Kenneth D. Director — — Series B-1 Warrants 102,366 0.92 94.2K 0 D ↗
2025-08-27 Lee-Sepsick Kathy Director / Officer I-Discretionary A Common Warrants (right to buy) 48,535 0.52 25.0K 48,535 D ↗
2025-08-27 Elefant Dov Officer I-Discretionary A Common Warrants (right to buy) 38,828 0.52 20.0K 38,828 D ↗
2025-06-25 Uzialko Edward R Director A-Award A Stock Option (Right to Buy) 17,600 0.98 17.2K 17,600 D ↗
2025-06-25 Silverman Joshua Director A-Award A Stock Option (Right to Buy) 17,600 0.98 17.2K 17,600 D ↗
2025-06-25 Milnes Alistair Director A-Award A Stock Option (Right to Buy) 17,600 0.98 17.2K 17,600 D ↗
2025-06-25 Larsen Charles Director A-Award A Stock Option (Right to Buy) 17,600 0.98 17.2K 17,600 D ↗
2025-06-23 Nicholas Kelley Stinson Officer A-Award A Stock Option (Right to Buy) 100,000 0.90 90.0K 100,000 D ↗
2025-06-02 Lee-Sepsick Kathy Director / Officer I-Discretionary A Common Stock 34,314 1.02 35.0K 312,092 D ↗
2025-06-02 Larsen Charles Director I-Discretionary A Common stock 24,510 1.02 25.0K 56 D ↗
2025-06-02 Elefant Dov Officer I-Discretionary A Common Stock 19,608 1.02 20.0K 19,608 D ↗
2025-06-02 Currie Daniel Scott Officer I-Discretionary A Common Stock 19,608 1.02 20.0K 86,275 D ↗
2025-01-29 Lee-Sepsick Kathy Director / Officer A-Award A Stock Option (Right to Buy) 120,353 1.17 140.8K 120,353 D ↗
2025-01-28 Thomas Christine E Officer A-Award A Stock Option (Right to Buy) 23,600 1.05 24.8K 23,600 D ↗
2025-01-28 Elefant Dov Officer A-Award A Stock Option (Right to Buy) 114,300 1.05 120.0K 114,300 D ↗
2025-01-28 Currie Daniel Scott Officer A-Award A Stock Option (Right to Buy) 29,184 1.05 30.6K 29,184 D ↗
2024-07-12 Uzialko Edward R Director A-Award A Stock Option (Right to Buy) 17,600 1.14 20.1K 17,600 — ↗
2024-07-12 Silverman Joshua Director A-Award A Stock Option (Right to Buy) 17,600 1.14 20.1K 17,600 — ↗
2024-07-12 Milnes Alistair Director A-Award A Stock Option (Right to Buy) 17,600 1.14 20.1K 17,600 — ↗
2024-07-12 Larsen Charles Director A-Award A Stock Option (Right to Buy) 17,600 1.14 20.1K 17,600 — ↗
2024-02-12 Spector Richard D. Officer A-Award A Stock Option (Right to Buy) 100,000 1.10 110.0K 100,000 — ↗
2024-02-01 Thomas Christine E Officer A-Award A Stock Option (Right to Buy) 32,600 0.80 26.1K 32,600 — ↗
2024-02-01 Lee-Sepsick Kathy Director / Officer A-Award A Stock Option (Right to Buy) 204,900 0.80 163.9K 204,900 — ↗
2024-02-01 Elefant Dov Officer A-Award A Stock Option (Right to Buy) 84,000 0.80 67.2K 84,000 — ↗
2024-02-01 Currie Daniel Scott Officer A-Award A Stock Option (Right to Buy) 61,900 0.80 49.5K 61,900 — ↗
2023-11-21 Silverman Joshua Director A-Award A Stock Option (Right to Buy) 17,000 0.90 15.3K 17,000 — ↗
2023-11-21 PharmaCyte Biotech, Inc. 10% Owner — D 6.0% Senior Convertible Note due 2025 4,237,288 1.18 5.00M 0 — ↗
2023-10-10 Thomas Christine E Officer A-Award A Stock Option (Right to Buy) 60,000 1.76 105.6K 60,000 — ↗
2023-07-03 Lee-Sepsick Kathy Director / Officer A-Award A Stock Option (Right to Buy) 271,900 0.49 133.2K 271,900 — ↗
2023-07-03 Elefant Dov Officer A-Award A Stock Option (Right to Buy) 204,700 0.49 100.3K 204,700 — ↗
2023-07-03 Currie Daniel Scott Officer A-Award A Stock Option (Right to Buy) 124,800 0.49 61.2K 124,800 — ↗
2023-06-21 Uzialko Edward R Director A-Award A Stock Option (Right to Buy) 8,500 0.57 4.8K 8,500 — ↗
2023-06-21 Perrow Wendy Director A-Award A Stock Option (Right to Buy) 8,500 0.57 4.8K 8,500 — ↗
2023-06-21 Morrissey Anne Director A-Award A Stock Option (Right to Buy) 8,500 0.57 4.8K 8,500 — ↗
2023-06-21 Larsen Charles Director A-Award A Stock Option (Right to Buy) 8,500 0.57 4.8K 8,500 — ↗
2023-06-14 Milnes Alistair Director A-Award A Stock Option (Right to Buy) 17,000 0.64 10.9K 17,000 — ↗
2023-06-14 Kendall Keith J Director A-Award A Stock Option (Right to Buy) 17,000 0.64 10.9K 17,000 — ↗
2022-10-10 Thomas Christine E Director A-Award A Stock Option (Right to Buy) 50,000 0.00 — 50,000 — ↗
2022-06-08 Uzialko Edward R Director A-Award A Stock Option (Right to Buy) 8,500 0.00 — 8,500 — ↗
2022-06-08 Perrow Wendy Director A-Award A Stock Option (Right to Buy) 8,500 0.00 — 25,500 — ↗
2022-06-08 Morrissey Anne Director A-Award A Stock Option (Right to Buy) 8,500 0.00 — 8,500 — ↗
2022-06-08 Larsen Charles Director A-Award A Stock Option (Right to Buy) 8,500 0.00 — 8,500 — ↗
2022-06-08 Dyett John Director A-Award A Stock Option (Right to Buy) 8,500 0.00 — 8,500 — ↗
2022-06-08 Adams John Q JR Director A-Award A Stock Option (Right to Buy) 8,500 0.00 — 8,500 — ↗
2022-02-28 Elefant Dov Officer A-Award A Stock Option (Right to Buy) 100,000 2.97 297.0K 100,000 — ↗
2022-01-25 Perrow Wendy Director A-Award A Stock Option (Right to Buy) 17,000 3.03 51.5K 17,000 — ↗
2022-01-25 Currie Daniel Scott Officer A-Award A Stock Option (Right to Buy) 20,000 3.03 60.6K 20,000 — ↗
2022-01-19 Perrow Wendy — — — — 0 0.00 — 0 — ↗
2021-12-15 Witte William Benson Director J-Other A Common Stock 12,191 0.00 — 12,191 — ↗
2021-12-15 Dyett John Director J-Other A Common Stock 175,635 0.00 — 290,344 — ↗
2021-09-01 Evantash Edward — — — — 0 0.00 — 0 — ↗
2021-06-23 Dyett John Director / 10% Owner P-Purchase A Common Stock 1,000 9.95 10.0K 114,709 — ↗
2021-06-22 Uzialko Edward R Director C-Conversion A Common Stock 30,175 0.00 — 30,175 — ↗
2021-06-22 Larsen Charles Director P-Purchase A Common Stock 7,000 13.00 91.0K 7,000 — ↗
2021-06-22 Dyett John Director / 10% Owner C-Conversion D Series B Convertible Preferred Stock 948,342 0.00 — 0 — ↗
2021-06-22 Adams John Q JR Director C-Conversion A Common Stock 91,245 0.00 — 131,245 — ↗
2021-06-18 Dyett John Director / 10% Owner P-Purchase A Common Stock 2,500 13.18 33.0K 2,500 — ↗
2021-06-17 Witte William Benson Director — D Employee Stock Option (Right to Buy) 3,334 3.24 10.8K 0 — ↗
2021-06-17 Uzialko Edward R Director / 10% Owner — D Warrants (Right to Buy) 4,762 31.50 150.0K 0 — ↗
2021-06-17 Thompson Gary Director — — Common Stock 0 0.00 — 3,334 D ↗
2021-06-17 Morrissey Anne — — — — 0 0.00 — 0 — ↗
2021-06-17 Lee-Sepsick Kathy Director / Officer — D Employee Stock Option (Right to Buy) 43,211 3.24 140.0K 0 — ↗
2021-06-17 Larsen Charles Director — D Series C Convertible Preferred Stock 10,587 0.00 — 0 — ↗
2021-06-17 Kelley Hoskin Violet Alexandria Officer — D Employee Stock Option (Right to Buy) 4,445 6.12 27.2K 0 — ↗
2021-06-17 Dyett John Director / 10% Owner — I Series B Convertible Preferred Stock 948,342 0.00 — 0 — ↗
2021-06-17 Currie Daniel Scott Officer — D Employee Stock Option (Right to Buy) 5,556 1.71 9.5K 0 — ↗
2021-06-17 Adams John Q JR Director — D Series C Convertible Preferred Stock 108,693 0.00 — 0 — ↗

Executive team

Top executives
EBIT / Employee
-2.4K
Shares Outstanding
29.45M

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2025 Kathy Lee-Sepsick President and Chief Executive Officer 542.0K 162.6K — — — 38.0K 1.14M 0.00% ↗
2 2025 Dov Elefant Chief Financial Officer 432.6K 97.3K — — — 64.4K 743.3K 0.00% ↗
3 2025 Daniel Currie Chief Operating Officer 384.0K — — — — 70.7K 638.8K 0.00% ↗
4 2024 Kathy Lee-Sepsick President and Chief Executive Officer 542.0K 81.3K — — — 37.9K 800.3K 0.00% ↗
5 2024 Dov Elefant Chief Financial Officer 432.6K 40.1K — — — 76.1K 605.8K 0.00% ↗
6 2024 Daniel Currie Chief Operating Officer 400.7K 48.7K — — — 31.9K 529.3K 0.00% ↗
7 2023 Kathy Lee-Sepsick President and Chief Executive Officer 500.0K 270.0K — — — 34.7K 1.02M 0.00% ↗
8 2023 Dov Elefant Chief Financial Officer 420.0K 151.2K — — — 23.9K 716.2K 0.00% ↗
9 2023 Daniel Currie Chief Operating Officer 389.0K 124.5K — — — 34.7K 630.4K 0.00% ↗
10 2022 Kathy Lee-Sepsick President and Chief Executive Officer 423.3K — — — — 30.3K 659.0K 0.00% ↗
11 2022 Dov Elefant Chief Financial Officer 335.2K — — — — 20.5K 601.6K 0.00% ↗
12 2022 Daniel Currie Senior Vice President, Operations 322.3K — — — — 30.3K 505.7K 0.00% ↗
13 2022 Daniel Currie Chief Operating Officer 322.4K — — — — 30.3K 505.7K 0.00% ↗
14 2021 Kathy Lee-Sepsick President and Chief Executive Officer 540.0K — — — — 26.7K 566.7K 0.00% ↗
15 2021 Daniel Currie Senior Vice President, Operations 384.8K — — — — 26.7K 411.5K 0.00% ↗
16 2021 Gary Thompson Vice President, Finance and Administration 106.9K — — — — — 106.9K 0.00% ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2026-04-30 DEFA14A ↗
2026-04-30 DEF 14A ↗
2026-04-06 DEF 14A ↗
2026-03-27 PRE 14A ↗
2025-04-28 DEFA14A ↗
2025-04-28 DEF 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-04-30 DEFA14A ↗
2026-04-30 DEF 14A ↗
2026-04-30 ARS ↗
2026-04-29 8-K ↗
2026-04-06 DEF 14A ↗
2026-04-01 8-K ↗
2026-04-01 4 ↗
2026-04-01 3 ↗
2026-03-31 S-8 ↗
2026-03-31 8-K ↗

Executive team

NameTitleCompensationGender
Kathy Lee-Sepsick Founder, President, Chief Executive Officer & Director 661.2K female
Dov Elefant Chief Financial Officer 548.8K male
James H. Liu Chief Medical Officer — —
Jeffrey Marcus Chief Medical Advisor — —
John Canning Chief Operating Officer — male
Mary An Merchant Vice President of Counsel & Intellectual Property — female
Megan Eckerman Senior Vice President of Global Marketing — female
Benjamin Dings Vice President of Sales — male
Naomi Phaneuf Vice President of Marketing — female
Christine Thomas Senior Vice President of Regulatory & Clinical Affairs — female
ESG Rating
B-
MEDICAL - INSTRUMENTS & SUPPLIES
2025
E (Environmental)
59.5 / 64.7
Company / Sector avg.
S (Social)
57.1 / 70.0
Company / Sector avg.
G (Governance)
56.8 / 67.5
Company / Sector avg.
ESG Total
57.8 / 67.4
Company / Sector avg.
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies